| Literature DB >> 23985033 |
Claudio Muscari1, Emanuele Giordano, Francesca Bonafè, Marco Govoni, Alice Pasini, Carlo Guarnieri.
Abstract
The efficiency of regenerative medicine can be ameliorated by improving the biological performances of stem cells before their transplantation. Several ex-vivo protocols of non-damaging cell hypoxia have been demonstrated to significantly increase survival, proliferation and post-engraftment differentiation potential of stem cells. The best results for priming cultured stem cells against a following, otherwise lethal, ischemic stress have been obtained with brief intermittent episodes of hypoxia, or anoxia, and reoxygenation in accordance with the extraordinary protection afforded by the conventional maneuver of ischemic preconditioning in severely ischemic organs. These protocols of hypoxic preconditioning can be rather easily reproduced in a laboratory; however, more suitable pharmacological interventions inducing stem cell responses similar to those activated in hypoxia are considered among the most promising solutions for future applications in cell therapy. Here we want to offer an up-to-date review of the molecular mechanisms translating hypoxia into beneficial events for regenerative medicine. To this aim the involvement of epigenetic modifications, microRNAs, and oxidative stress, mainly activated by hypoxia inducible factors, will be discussed. Stem cell adaptation to their natural hypoxic microenvironments (niche) in healthy and neoplastic tissues will be also considered.Entities:
Mesh:
Year: 2013 PMID: 23985033 PMCID: PMC3765890 DOI: 10.1186/1423-0127-20-63
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
Figure 1Efficacy of hypoxic pretreatments of adult SCs in regenerative medicine. Grafted SCs become more resistant to the death stimuli that are present in the injured tissues through ex-vivo hypoxic pretreatments (continuous hypoxia or cyclic hypoxia-anoxia and reoxygeneation) or by administration of CoCl2. Pharmacological agents exerting intracellular key effects of hypoxic preconditioning, such as diazoxide, can also be effective. The most common sensor activated under low oxygen tensions is HIF-1α which increases cell survival by stimulating several pathways, including glycolytic flow, Akt phosphorylation, and miRs upregulation. Transgenic induction of miR-107 and miR-210, which are mainly expressed after hypoxia, also provides protection to SCs against the engraftment injury.
Figure 2Schematic representation of hypoxia-induced epigenetic changes. Hypoxic conditions modulate SCs expression profile via several mechanisms, included epigenetic modifications. The induced upregulation of HIF-1α and HIF-2α, drives the activation of several target genes. Also stem-related genes, such as OCT-4, could be re-expressed. The chromatin configuration of their promoter region becomes accessible to transcription factors, also consequently to the upregulation of histone demethylases JMJD1A and JMJD2B, that catalyse the removal of repressive histone marks (H3K9me2/3). Histone tails are characterized by active histone modifications (light or dark blue squares), such as acetylated H3-H4 or H3K4me2/3, and DNA is unmethylated (white rounds) at the promoter CpG sites (black lines). Hypoxia also induced global repression of gene transcription, associated with the upregulation of chromatin modifier enzymes, such as histone deacetylases (HDACs) and demethylases (G9a), that drive the formation of histone repressive marks (red and purple rounds), such as deacetylated H3-H4, H3K9me2/3 or H3K27me3. DNA methylation global level increases consequently to the upregulation of DNA methyltransferases (DNMTs) and gene expression is silenced. MiRNAs additional control of transcription and translation contributes to generate a gene expression profile that allows to reactivated stem-related genes, increase protection from oxidative stress, reduce DNA damage, increase glycolysis and angiogenesis, with the final result of enhancing cell viability and their regenerative potential.
Effects of reduced oxygen tension on SC survival
| Mouse peripheral blood mononuclear cells | Continuous hypoxia | Increased oxidative stress resistance | Ischemic hind limb/increased angiogenesis | [ |
| Rat MSCs | Continuous hypoxia | Reduced apoptosis/activation of Akt, ERK, NADPH oxidase | | [ |
| BM-MSCs | Continuous hypoxia | Akt activation and cMET upregulation | Ischemic hind limb/increased angiogenesis | [ |
| Skeletal myoblasts | Cyclic hypoxia | Improved resistance to lethal anoxia | | [ |
| Human MSCs | Continuous hypoxia | | Infarcted swine heart/ increased cardiac contractility and angiogenesis | [ |
| BM-MSCs | Anoxia | Reduced apoptosis | Diabetic cardiomyopathy/reduced remodeling | [ |
| Murine MSCs | Continuous hypoxia | Increased Wnt4 expression | Ischemic hind limb/increased angiogenesis and MSC retention, proliferation, migration | [ |
| Mouse BM-MSCs | Continuous hypoxia | HIF-1α-dependent CXCR4 and CXCR7 overexpression | Ischemic and reperfused kidney/ increased MSC survival, recruitment, proliferation | [ |
| MSCs | CoCl2 | HIF-1α-dependent CXCR4 overexpression | Acute kidney ischemia/ increased MSC retention, migration | [ |
| HUVECs | Cyclic hypoxia | Increased cicloxygenase-2 | | [ |
| MSCs | Cyclic hypoxia | HIF-1α dependent activation of Akt and miR-210 and CAP8AP2 upregulation | Infarcted heart/higher MSC survival | [ |
| MSCs | Transgenic induction of miR-210 | Increased CASP8AP2 expression | Infarcted heart/improved MSC grafting and cardiomyocyte protection | [ |
| Endothelial cells | Continuous hypoxia | Reduced apoptosis/HIF-1α dependent miR-210 upregulation and receptor tyrosine kinase ligand Ephrin-A3 inhibition | | [ |
| MSCs | Cyclic hypoxia | HIF-1α-dependent Akt and miR-107 activation and PDC10 inhibition | Infarcted heart/increased MSC survival | [ |
| MSCs | diazoxide | NF-kB activation | | [ |
| Skeletal myoblasts (SMs) | diazoxide | Prevented apoptosis/activation of Akt, bFGF, HGF, cycloxigenase-2 | Infarcted rat heart/higher SM survival and increased cardiac contractility, angiogenesis | [ |
Chemicals and cytokines useful for preconditioning SCs before their transplantation
| Neural SCs | isoflurane
[ |
| EPCs | sevoflurane
[ |
| MSCs | oxytocin
[ |
| ADSCs | sydenafil
[ |
| Cardiac SCs | cobalt protoporphyrin
[ |
Effects of reduced oxygen tension on SC differentiation
| BM-MSCs | CoCl2 | Dopaminergic neuron-like cells/HIF-1α dependent activation of EPO, VEGF, p21 | [ |
| Rat MSCs | Continuous hypoxia | Increased chondrogenesis/activation of HIF-1α, Akt, p38 MAPK, SOX-9 | [ |
| Human MSCs | Continuous hypoxia | Inhibited osteogenesis/ HIF-1α dependent inhibition of RUNX2 | [ |
| MSCs | Continuous hypoxia | Inhibited hypertrophic chondrogenesis | [ |
| BM-MSCs | Continuous hypoxia in alginate beads | Increased chondrogenesis/ HIF-1α dependent stimulation of SOX-9 | [ |
| Human BM-MSCs | Continuous hypoxia in gelatine hydrogel | Increased chondrogenesis | [ |
| Human ADSCc | Continuous hypoxia and chondrogenic medium | Increased chondrogenesis | [ |
| ADSCc | Continuous 2% oxygen tension | Decreased chondrogenesis and osteogenesis | [ |